Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Health GroupHKSE:00673 24 EBITDA Margin % is -178.98% as of Mar. 2026. GuruFocus rates HKSE:00673 with a GF Score™ of 24/100 and a GF Value™ of HK$0.24 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 119 Medical Distribution companies, China Health Group ranks worse than 97.48% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. China Health Group's EBITDA for the
six
months ended in Mar. 2026 was HK$-38.45 Mil. China Health Group's Revenue for the
six
months ended in Mar. 2026 was HK$21.48 Mil. Therefore, China Health Group's EBITDA margin for the quarter that ended in Mar. 2026 was -178.98%.
China Health Group (HKSE:00673) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
China Health Group EBITDA Margin % Related Terms
China Health Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for China Health Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:00673 vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, China Health Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Health Group EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China Health Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where China Health Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Health Group (HKSE:00673) has a EBITDA Margin % of -178.98% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on China Health Group and its competitors. According to the industry distribution chart, China Health Group ranks #116 out of 119 companies in the Medical Distribution industry, placing it in the top 97.5%.
Is China Health Group's EBITDA Margin % too high?
China Health Group's current EBITDA Margin % is -178.98%. Based on the distribution chart, China Health Group ranks #116 out of 119 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, China Health Group has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Health Group's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, China Health Group ranks #116 out of 119 companies for EBITDA Margin %. This places China Health Group in the lower half of its industry. The industry median EBITDA Margin % is 4.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.28, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on China Health Group and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Health Group's current EBITDA Margin % is -178.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Health Group stock overvalued right now?
Based on GuruFocus' analysis, China Health Group (HKSE:00673) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.24, compared to a current price of HK$0.40 — trading 66.7% above its estimated fair value. The current EBITDA Margin % is -178.98%. China Health Group's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For China Health Group (HKSE:00673), the current EBITDA Margin % is -178.98% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Health Group (HKSE:00673) Overvalued in 2026?
Based on GuruFocus' analysis, China Health Group stock appears to be overvalued.
The current stock price of HK$0.40 is trading 66.7% above its estimated GF Value™ of HK$0.24.
GuruFocus considers China Health Group to be Significantly Overvalued.
Key valuation signals for HKSE:00673:
EBITDA Margin %: -178.98%
GF Value™: HK$0.24 vs. price of HK$0.40 (66.7% above fair value)
No single metric tells the full story. See the HKSE:00673 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Health Group Ltd is an investment holding company. It is principally engaged in the distribution and service of medical equipment and consumables, provision of hospital operation and management services, and business factoring. It operates in the business in four segments: medical equipment and consumables distribution and service business; hospital operation and management services business; business service; and research and development and sale of functional food. It derives a majority of revenue from the Distribution and service in the medical equipment and consumables segment. Geographically, the group derives its revenue from the PRC.
24GF Score
Get the complete analysis for HKSE:00673
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00673 has been successfully added to your 
